Acrivon Therapeutics, Inc. SEC filings ACRV
Acrivon Therapeutics, Inc. has 346 filings in SEC EDGAR's recent list, going back to Feb 12, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Aug 12, 2026 | — |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 17, 2026 | Jun 17, 2026 |
| DEFA14A | Additional proxy material | May 22, 2026 | — |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 17, 2026 |
| S-8 | Employee stock plan registration | Mar 19, 2026 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 19, 2026 | Mar 19, 2026 |
| 10-K | Annual report | Mar 19, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Agreement ended
|
Mar 2, 2026 | Feb 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 27, 2026 | Feb 27, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2025 | Nov 13, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 5, 2025 | Sep 5, 2025 |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2025 | Aug 13, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2025 | Jun 13, 2025 |
| S-8 | Employee stock plan registration | May 14, 2025 | — |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| ARS | Annual report to shareholders | Apr 25, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 13, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 7, 2025 | Apr 7, 2025 |
| S-8 | Employee stock plan registration | Mar 28, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 27, 2025 | Mar 27, 2025 |
| 10-K | Annual report | Mar 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Mar 25, 2025 | Mar 25, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 14, 2025 | Mar 11, 2025 |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 11, 2024 | Oct 11, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 16, 2024 | Sep 14, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2024 | Jun 20, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| EFFECT | Filing | Apr 29, 2024 | — |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 20, 2024 |
| CORRESP | Letter to the SEC | Apr 24, 2024 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Apr 24, 2024 | Apr 24, 2024 |
| UPLOAD | Letter from the SEC | Apr 19, 2024 | — |
| S-3 | Shelf registration | Apr 17, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Apr 9, 2024 | Apr 8, 2024 |
| S-8 | Employee stock plan registration | Mar 29, 2024 | — |
| 8-K |
Current report
Results of operations
|
Mar 28, 2024 | Mar 28, 2024 |
| 10-K | Annual report | Mar 28, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 4, 2024 | Mar 4, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 8, 2024 | Feb 7, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2024 | Jan 8, 2024 |
| EFFECT | Filing | Dec 15, 2023 | — |
| CORRESP | Letter to the SEC | Dec 12, 2023 | — |
| 8-K |
Current report
Material agreement
|
Dec 8, 2023 | Dec 4, 2023 |
| UPLOAD | Letter from the SEC | Dec 5, 2023 | — |
| S-3 | Shelf registration | Dec 1, 2023 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 9, 2023 | Nov 9, 2023 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 5, 2023 | Sep 5, 2023 |
| S-8 | Employee stock plan registration | Aug 11, 2023 | — |
| 8-K |
Current report
Results of operations
|
Aug 11, 2023 | Aug 11, 2023 |
| 10-Q | Quarterly report | Aug 11, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2023 | Jun 22, 2023 |
| 8-K |
Current report
Material agreement
|
Jun 5, 2023 | May 30, 2023 |
| DEFR14A | Filing | May 30, 2023 | — |
| 8-K |
Current report
Results of operations
|
May 9, 2023 | May 9, 2023 |
| 10-Q | Quarterly report | May 9, 2023 | Mar 31, 2023 |
| ARS | Annual report to shareholders | May 1, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEF 14A | Proxy statement | May 1, 2023 | Jun 22, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
May 1, 2023 | May 1, 2023 |
| 8-K |
Current report
Results of operations
|
May 1, 2023 | May 1, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 25, 2023 | Apr 25, 2023 |
| S-8 | Employee stock plan registration | Mar 29, 2023 | — |
| 10-K | Annual report | Mar 28, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2023 | Mar 28, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 13, 2023 | Mar 13, 2023 |
| 8-K |
Current report
Other events
|
Mar 3, 2023 | Mar 3, 2023 |
| 10-Q | Quarterly report | Dec 15, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Unregistered share sale, Bylaw or fiscal year change, Other events
|
Nov 17, 2022 | Nov 14, 2022 |
| S-8 | Employee stock plan registration | Nov 17, 2022 | — |
| 424B4 | Prospectus | Nov 16, 2022 | — |
| S-1MEF | Filing | Nov 14, 2022 | — |
| FWP | Free writing prospectus | Nov 14, 2022 | — |
| SEC STAFF LETTER | Filing | Nov 9, 2022 | — |
| EFFECT | Filing | Nov 9, 2022 | — |
| CERT | Filing | Nov 8, 2022 | — |
| S-1/A | Amended registration statement | Nov 8, 2022 | — |
| CORRESP | Letter to the SEC | Nov 7, 2022 | — |
| CORRESP | Letter to the SEC | Nov 7, 2022 | — |
| 8-A12B | Filing | Nov 7, 2022 | — |
| S-1/A | Amended registration statement | Nov 3, 2022 | — |
| CORRESP | Letter to the SEC | Oct 17, 2022 | — |
| S-1 | Registration statement | Oct 17, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2022 | — |
| DRSLTR | Filing | Sep 22, 2022 | — |
| DRS/A | Filing | Sep 22, 2022 | — |
| SEC STAFF LETTER | Filing | Sep 14, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 12, 2022 | — |
| DRS | Filing | Aug 12, 2022 | — |
| D | Filing | Nov 23, 2021 | — |
| D | Filing | Feb 12, 2021 | — |
Showing 110 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACRV (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Watertown, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1781174
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.